53 results about "CD29" patented technology

Methods for the identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. Specifically, this invention relates to an adult multipotent cell or a cell population or composition comprising said cell, isolated from non-osteochondral mesenchymal tissue, characterized in that the cell is positive for the following markers: CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 and CD105 and because it lacks expression of the following markers: CD11b, CD14, CD15, CD16, CD31, CD34, CD45, CD49f, CD102, CD104, CD106 and CD133.

The present invention relates to placenta tissue-derived multipotent stem cells and cell therapeutic agents containing the same. More specifically, to a method for producing placenta stem cells having the following characteristics, the method comprising culturing amnion, chorion, decidua or placenta tissue in a medium containing collagenase and bFGF and collecting the cultured cells: (a) showing a positive immunological response to CD29, CD44, CD73, CD90 and CD105, and showing a negative immunological response to CD31, CD34, CD45 and HLA-DR; (b) showing a positive immunological response to Oct4 and SSEA4; (c) growing attached to plastic, showing a round-shaped or spindle-shaped morphology, and forming spheres in an SFM medium so as to be able to be maintained in an undifferentiated state for a long period of time; and (d) having the ability to differentiate into mesoderm-, endoderm- and ectoderm-derived cells. Also the present invention relates to placenta stem cells obtained using the production method. The inventive multipotent stem cells have the ability to differentiate into muscle cells, vascular endothelial cells, osteogenic cells, nerve cells, satellite cells, fat cells, cartilage-forming cells, osteogenic cells, or insuline-secreting pancreatic β-cells, and thus are effective for the treatment of muscular diseases, osteoporosis, osteoarthritis, nervous diseases, diabetes and the like, and are useful for the formation of breast tissue.

Populations enriched for myogenic progenitors are obtained by selection on the basis of expression of specific cell surface markers. The muscle progenitor cells are characterized as being CD45⁻ and CD34⁺, and may further be characterized as lacking expression of Mac-1 (CD11b) and positive for expression of CXCR4 (CD184) and β1-integrin (CD29).

Compositions comprising menstrual stem cells (MSCs) and methods, processes, and system therefor are provided by the invention. MSCs are processed from menstrual flow collected during menses. MSCs may be cryopreserved, processed through various culturing and selection steps in preparation for cryopreservation, or processed for therapeutic or cosmeceutical use. Cryopreserved MSCs may be thawed in preparation for therapeutic and cosmeceutical use. MSCs express CD9, CD10, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, and HLA class I, and have low or no expression of CD3 and HLA class II.

The invention discloses a method for separately culturing a human adipose mesenchymal stem cell and a dedicated culture medium thereof. The culture medium used for separately culturing the human adipose mesenchymal stem cell comprises an animal cell basic culture medium, fetal calf serum, an epidermal growth factor and a platelet-derived growth factor. The final concentration of the fetal calf serum is 1-200 mL/L, the final concentration of the epidermal growth factor is 1-100 ng/ml, and the final concentration of the platelet-derived growth factor is 1-100 ng/ml. The adipose mesenchymal stem cell of the invention has CD31-, CD34-, CD45- and HLA-DR-, as well as the phenotype of CD29+, CD44+, CD105+ and Flk-1+. The specificity cell surface marker and the relevant antihelion molecule of a skeletal muscle cell and a vascular endothelia cell can be expressed after inducement is performed in vitro. Muscle fiber, vascular endothelin and functional muscle satellite cells can be differentiated in a muscle injury model mouse body caused by medicine and the expression of dystrophin protein on the ducheme muscular dystrophy (DMD) model mouse (mdx) myolemma can be partially recovered, so as to release the pathological symptom of the model mouse.

The invention discloses separation, purification and identification methods of human amnion mesenchymal stem cells. The separation method of hAMSCs (human amnion mesenchymal stem cells) comprises the following steps: fragmentating human amnion; and carrying out two-step rotating digestion with trypsin of EDTA (ethylene diamine tetra-acetic acid) and collagenase of DNaseI, filtering with a steel mesh and collecting cell filtrate namely separated original hAMSCs. The purification method of hAMSCs comprises the following steps: incubating original hAMSCs with an LG (low glucose)-DMEM (dulbecco modified eagle medium) culture medium in a CO2 incubator; removing amnion epithelial cells which do not perform complete adherence growth under an inverted microscope; replacing a new culture medium on the third day; digesting with a trypsin-EDTA solution after cell converge degree reaches 80-90%; and collecting cells so as to obtain high-purity hAMSCs. The identification method of hAMSCs comprises the following steps: identifying hAMSCs and the amnion epithelial cells by adopting immunocytochemical staining vimentin and CK19; and detecting expressions of CD29, CD44, CD166, CD34 and CD45 by adopting a flow cytometry. The separation and purification methods disclosed by the invention have the advantages of high yield, high activity and high purity of hAMSCs; and the identification method is simple, convenient and precise.

The invention discloses a stem cell preparation for treating primary liver cancer and a preparation method thereof. The preparation contains (60-100)*10<6> pieces/ml of mesenchymal stem cells, 20ng/ml of HGF and 10ng/ml of FGF-4, and takes autologous platelet-rich plasma lysate as a solvent. The preparation method comprises the following steps of: (1) collecting an umbilical cord, and carrying out primary culture to obtain cells; (2) detecting by using a flow cytometry, wherein such cells express CD29, CD73, CD90 and CD105; (3) collecting cells, namely dissolving (60-100)*10<6> mesenchymal stem cells of the human umbilical cord in 1 ml of autologous platelet-rich plasma lysate, and adding 20ng of HGF and 10ng of FGF-4 to be prepared into 1 ml of a stem cell preparation. According to the stem cell preparation disclosed by the invention, the source of raw materials is rich, the raw materials are easy to obtain, the umbilical cord mesenchymal stem cells are weakly immunogenic, and platelet-rich plasma is taken from the patients, so no immunogenicity exists.

The present invention relates to multipotent adult stem cells expressing Oct4, derived from umbilical cord blood (UCB) and also these cell are expressing CD29, CD31, CD44, simultaneously, a method for preparing the same, and more specifically to multipotent adult stem cells which are obtained by culturing umbilical cord blood-derived monocytes in a medium containing bFGF (basic fibroblast growth factor) and human serum or plasma. In addition, multipotent adult stem cells expressing Oct-4 from UCB are morphologically spindle or round shaped cells Although the stem cells according to the present invention are adult stem cells, they are multipotent and capable of differentiating into ectodermal-, messodermal-, endodermal-originated tissue or cells including osteogenic cells or nerve cells etc, thus they can be effectively used in the treatment of intractable diseases and incurable diseases.

The present invention provides a method for producing mesenchymal cells for production of mesenchymal cells for formation of a tooth, the method comprising: culturing totipotent stem cells in the presence of a differentiation inducer to produce a cell population after differentiation induction treatment, the cell population containing CD44-positive and CD29-positive cells or CD44-positive and CD 106-positive cells; and selecting, from the cell population after the differentiation induction treatment, the CD44-positive and CD29-positive cells or CD44-positive and CD 106-positive cells as the mesenchymal cells for the formation of the tooth. The present invention also provides a method for producing a tooth comprising: positioning, in a support carrier capable of retaining cells in a state of contacting therewith, a first cell mass substantially consisting of only either one of mesenchymal cells and epithelial cells and a second cell mass substantially consisting of only the other one of the mesenchymal cells and epithelial cells, the first and second cell masses being not mixed with each other but made to closely contact with each other; and culturing the first and second cell masses; wherein the mesenchymal cells comprise the mesenchymal cells for the formation of the tooth.

The invention provides a preparation for mobilizing mesenchymal stem cells and a method for separating the mesenchymal stem cells. The preparation for mobilizing the mesenchymal stem cells comprises CoCl2, wherein the CoCl2 is a hypoxia mimetic agent, and the dosage is in a range of 5-20mg/kg. The CoCl2 and AMD3100 are used in a combined manner. The dosage of the AMD3100 is 5mg/kg. According to the method for separating the mesenchymal stem cells by using the preparation, the preparation is used for actuating the mesenchymal stem cells to be mobilized, enter peripheral blood and then be separated. The method comprises the following separation steps of: sampling the periphery blood, separating mononuclear cells by using a lymphocyte separating medium, performing resuspension by using a DMEM (dulbeccos modified eagle medium) containing 20% of fetal bovine serum, inoculating to a culture flask, culturing for 7 days, and changing a culture solution, thus obtaining the mesenchymal stem cells of the peripheral blood on the 10th day. The mesenchymal stem cells of the peripheral blood highly express CD90, CD29 and CD44, do not express CD45 and CD34, and have the capacities of in vitro bone formation, fat formation and cartilage differentiation formation. The preparation is high in MSCs (mesenchymal stem cells) mobilization efficiency, and an effective preparation and an effective method are provided for tissue engineering and regenerative medicine.

The invention discloses a method for extracting a paracrine factor from adipose-derived stem cells. The method comprises the following steps: taking a collected fat sample, and washing the fat samplewith normal saline for 1-3 times; adding a proper amount of adipose cell digestive juice for digestion; performing centrifugation, resuspending cell precipitate, and performing primary culture with aserum-free medium; performing subculture; performing enlarged culture; and performing extraction with a paracrine factor extracting solution, and performing purification to obtain the paracrine factor, wherein the paracrine factor extracting solution is prepared from a PBS buffer solution, L-glutamine, D-glucose and L-ascorbic acid, and the concentrations of the L-glutamine, the D-glucose and theL-ascorbic acid are 1-3mmol/L, 10-20 micromoles/L and 10-100 micromoles/L respectively. The method disclosed by the invention can stably extract the adipose-derived stem cells from adipose tissues, and extract the paracrine factor of the adipose-derived stem cells by utilizing the adipose-derived stem cells, so that the cell quality and the factor extraction efficiency are stable; and the adipose-derived stem cells are separated and cultured for a long time in a GMP environment, do not contact any animal-derived component, and can efficiently express adipose-derived stem cell markers such as CD29, CD44 and CD105.

An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.

The purpose of the present invention is to provide: new mesenchymal stem cells having excellent therapeutic effect on various diseases, a new pharmaceutical composition containing the mesenchymal stemcells, and a method for preparing the same. The present invention is ROR1-positive mesenchymal stem cells. Preferably, the ROR1-positive mesenchymal stem cells are CD29-, CD73-, CD90-, CD105-, and CD166-positive, and are derived from an umbilical cord or fat.

The purpose of the present invention is to provide the following: novel mesenchymal stem cells having an excellent therapeutic effect on various diseases, particularly diseases associated with fibrosis; and a pharmaceutical composition containing such mesenchymal stem cells. The present invention is a therapeutic agent for fibrosis that contains ROR1-positive mesenchymal stem cells and/or a culture supernatant thereof and that is for preventing or treating a disease associated with fibrosis. The mesenchymal stem cells are CD29-, CD73-, CD90-, CD105-, and CD166-positive and are preferably derived from the umbilical cord or fat. In addition, the abovementioned disease associated with fibrosis is preferably a liver disease, a lung disease, a kidney disease, or a heart disease.

The invention relates to a cell preparation for treating inflammatory enteritis. The cell preparation is a mesenchymal stem cell preparation of Wharton's jelly of human umbilical cord; the cell preparation is derived from mesenchymal stem cells from Wharton's jelly of fetal umbilical cord; and the positive rates of CD29, CD44, CD90 and CD105 of the cell preparation detected and identified througha flow cytometry are all more than 90%, and preferably, more than 95%.

The invention discloses an extracting method of dog adipose-derived stem cells, and a preparation and application of the dog adipose-derived stem cells. The preparation for treating dog chronic nephrosis is prepared from the dog allogeneic adipose-derived stem cells. The extracting method of the adipose-derived stem cells comprises the steps: the dog abdominal adipose tissue is obtained, digesting, filtering and centrifuging are conducted, red blood cell lysis buffer resuspending is conducted, and the cells of P0-P3 generations are cultured; and the obtained adipose-derived stem cells of the P3 generation are subjected to surface antigen testing, the adipose-derived stem cells which have more than 70% of CD29 and MHC-1 expressions, less than 2% of CD34 and CD45 expressions, and the high differentiative potential, achieve adipogenesis, osteogenesis and chondrogenesis, and have normal chromosomes, feminine endotoxin and nont-detected mycoplasma are screened out and resuspended with the dosage of 1*10<6> cells/kg-5*10<6> cells/kg through normal saline of 0.5-1.0 mL to prepare the application of the dog allogeneic adipose-derived stem cells, and the preparation is used for treating dogchronic nephrosis. The stem cell preparation is weak in immunogenicity and is not involved in argument in the aspects of society, ethic and law; a transplanted person does not need to provide autologous stem cells, and nearly no damage is caused; and a separating method is simple, and the cells are very high in activity and easy to increase massively.

The invention discloses an application method of CD29 in identification and sorting of human-placenta-chorion-avillosum-derived mesenchymal stem cells. According to the application method disclosed bythe invention, the human-placenta-chorion-avillosum-derived mesenchymal stem cells (PMSCs) are firstly marked with a variety of cell surface markers separately, then, detection is carried out by using a flow cytometer to survey qualified rate and stability of flow-type detection marked with all the markers, and it is discovered that the expression of a marker CD90 in a universal standard is unstable, and detections are all qualified after the PMSCs are marked with the CD29; and through repeated test, it is discovered that the CD29 has good detection stability, the qualified rate of detectionis 100%, thus, the CD29 has a good and stable identification effect on the PMSCs and can be applied to rapid and accurate identification on the PMSCs instead of the CD90.

The invention discloses a CD29<+> human umbilical cord-derived mesenchymal stem cell and an application thereof in preparation of a bone tissue engineering seed cell used for treating bone injury. The CD29<+> human umbilical cord-derived mesenchymal stem cell expresses the following four mesenchymal stem cell membrane molecules: a human leukocyte differentiation antigen CD73, a human leukocyte differentiation antigen CD90, a human leukocyte differentiation antigen CD105 and a human leukocyte differentiation antigen CD29. The CD29<+> human umbilical cord-derived mesenchymal stem cell disclosed by the invention can be converted into a bone cell in a mouse to participate in fracture healing, has low immunogenicity and can be taken as a cell source of tissue-engineered bone, then the traditional surgical therapy scheme is combined, and a good therapeutic effect can be achieved, so that the CD29<+> human umbilical cord-derived mesenchymal stem cell disclosed by the invention has a broad application prospect.

The invention discloses a culture method of human umbilical cord-derived Muse cells. The culture method comprises the following steps: determining participants, determining experimental instruments and reagents, determining an experimental method, separating the Muse cells, and performing in-vitro amplification culture on the Muse cells. The method has the beneficial effects that by applying the culture system, the MSCs obtained by separation are in a typical fibroblast form and have relatively strong multiplication capacity. According to the Muse cell culture method disclosed by the invention, the Muse cells are in positive expression, CD29, CD44, CD90 and CD105 are all in positive expression, and CD34 and CD45 are in negative expression, so that the Muse cells with relatively high purity can be obtained by the culture method, and a certain reference is provided for clinical application of the Muse cells in mesenchymal stem cell treatment, tissue regeneration, immunoregulation and the like in future.